The statement of Merck & Co., Inc. (NYSE:MRK) regarding review of FDA of Incretin based therapies.


Dallas, Texas 07/29/2013 (Financialstrend) – Merck & Co., Inc. (NYSE:MRK) closed in the previous trading session at $48.49 after going 0.66% (or +$0.32) in the northwards direction. The stock has hit day’s high at $48.49 and day’s low at $47.78.

Merck & Co., also known as MSD outside the Canada and United States, issued the following statement which involved the conclusion of the EMA’s (European Medicines Agency) CHMP (Committee for Medicinal Products for Human Use) review of incretin based or GLP-1 based therapies, including sitagliptin. The European Medicines Agency issued a news release recently, which said that the investigation which was made into GLP-1 based diabetes therapies had concluded and on the basis of available evidence, No new concerns for GLP-1 therapies have been identified.

The Managing Director, chief medical officer and executive vice president, Merck, Michael Rosenblatt said that the company appreciates the important role that is played by European Medicines Agency and its Committee for Medicinal Products for Human Use in monitoring the safety of medicines in Europe. He added that nothing is more important to the company other than ensuring the safety of their medicines and the people who take them. He further said that the company is confident in the safety profile of sitagliptin. Sitagliptin is an important medicine that will help adults with 2nd type diabetes to lower their levels of blood sugar.

The United States FDA (Food and Drug Administration) issued a Drug Safety Communication on the drugs that are based on incretin, including sitagliptin. The statement showed that Food and Drug Administration has not found out something new regarding safety risks with incretin mimetic drugs. In fact, the statement recommended that patients can continue to take their medicine until they talk to their doctor and that doctor continue to follow the task of prescribing recommendations in the drug labels.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.